ASTRAZENPharmaceuticals
AstraZeneca Pharma India Ltd — Cash Flow Statement
₹7765.50
-5.75%
AstraZeneca Pharma India Ltd Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Interest Received Cfi | 31.84 Cr | 32.09 Cr | 23.15 Cr | 11.11 Cr | — |
| Net PPE Purchase And Sale | -1.04 Cr | -10.35 Cr | -5.04 Cr | -6.37 Cr | — |
| Sale Of PPE | 0.71 Cr | 0.41 Cr | 3.48 Cr | 3.25 Cr | — |
| Purchase Of PPE | -1.75 Cr | -10.76 Cr | -8.52 Cr | -9.62 Cr | — |
| Operating Cash Flow | 65.36 Cr | 27.87 Cr | 58.29 Cr | 100.80 Cr | — |
| Taxes Refund Paid | -64.19 Cr | -56.43 Cr | -40.82 Cr | -24.79 Cr | — |
| Change In Working Capital | -103.22 Cr | -128.17 Cr | -30.19 Cr | 32.89 Cr | — |
| Change In Other Current Liabilities | 22.45 Cr | -1.95 Cr | 16.24 Cr | 10.60 Cr | — |
| Change In Other Current Assets | -33.51 Cr | -7.44 Cr | -6.47 Cr | -9.52 Cr | — |
| Change In Payable | 259.81 Cr | -31.37 Cr | 37.44 Cr | 12.05 Cr | — |
| Change In Inventory | -320.62 Cr | -37.67 Cr | -49.99 Cr | 19.58 Cr | — |
| Change In Receivables | -31.69 Cr | -50.62 Cr | -23.63 Cr | -4.71 Cr | — |
| Other Non Cash Items | -30.10 Cr | -31.37 Cr | -22.49 Cr | -10.53 Cr | — |
| Stock Based Compensation | 5.14 Cr | 2.74 Cr | 2.37 Cr | 1.82 Cr | — |
| Provisionand Write Offof Assets | 61.98 Cr | 5.26 Cr | 1.67 Cr | 4.00 Cr | — |
| Depreciation And Amortization | 39.99 Cr | 14.94 Cr | 16.26 Cr | 16.95 Cr | — |
| Amortization Cash Flow | 1.45 Cr | 0.13 Cr | 0.00 | — | — |
| Depreciation | 39.99 Cr | 14.94 Cr | 16.26 Cr | 16.95 Cr | — |
| Net Foreign Currency Exchange Gain Loss | -0.74 Cr | 0.15 Cr | -0.15 Cr | -0.05 Cr | — |
| Gain Loss On Sale Of PPE | -0.32 Cr | -0.03 Cr | -2.49 Cr | -2.82 Cr | — |
| Net Income From Continuing Operations | 156.36 Cr | 219.54 Cr | 134.10 Cr | 83.04 Cr | — |
| Free Cash Flow | 63.61 Cr | 17.11 Cr | 49.77 Cr | 91.18 Cr | — |
| Capital Expenditure | -1.75 Cr | -10.76 Cr | -8.52 Cr | -9.62 Cr | — |
| End Cash Position | 536.14 Cr | 505.57 Cr | 500.34 Cr | 448.42 Cr | — |
| Beginning Cash Position | 505.57 Cr | 500.34 Cr | 448.42 Cr | 352.34 Cr | — |
| Changes In Cash | 30.57 Cr | 5.23 Cr | 51.92 Cr | 96.08 Cr | — |
| Financing Cash Flow | -65.59 Cr | -44.38 Cr | -24.48 Cr | -9.46 Cr | — |
| Interest Paid Cff | -0.06 Cr | 0.00 | -0.63 Cr | -0.95 Cr | — |
| Cash Dividends Paid | -60.00 Cr | -40.00 Cr | -20.00 Cr | -5.00 Cr | — |
| Common Stock Dividend Paid | -60.00 Cr | -40.00 Cr | -20.00 Cr | — | -5.00 Cr |
| Investing Cash Flow | 30.80 Cr | 21.74 Cr | 18.11 Cr | 4.74 Cr | — |
| Net Other Investing Changes | — | — | -8000.00 | — | — |
| Other Cash Adjustment Outside Changein Cash | — | — | 8000.00 | 20000.00 | -2000.00 |
| Net Investment Purchase And Sale | — | — | — | 0.00 | 169.00 Cr |
| Sale Of Investment | — | — | — | 0.00 | 169.00 Cr |
| Purchase Of Investment | — | — | — | — | 0.00 |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on AstraZeneca Pharma India Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.